For investors in Singapore

Agustin Mohedas, Ph.D.

Research Analyst

Agustin Mohedas, Ph.D. is a Research Analyst at Janus Henderson Investors focused primarily on stocks in the biotechnology sector, a position he has held since 2019. Before joining the firm, Dr. Mohedas was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.

Dr. Mohedas received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a Ph.D. in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His Ph.D. research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 7 years of financial industry experience.

Articles Written

Understanding the impact of Delta

Understanding the impact of Delta

The highly infectious variant of COVID-19 has led to rising case numbers, but we explain why a return to normalcy is still within striking distance.

Biopharma’s targeted approach to growth
Quick Views Healthcare

Biopharma’s targeted approach to growth

A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.

COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks

COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks

Making sense of the latest developments around COVID-19 variants and what investors should consider now.

COVID-19 vaccine beats expectations

COVID-19 vaccine beats expectations

How a novel vaccine candidate from Pfizer and BioNTech could shape the trajectory of the global pandemic.